medigraphic.com
ISSN 2796-9711 (Print)
Publicación de la Asociación Salud, Ciencia y Tecnología

2022, Number 1

<< Back Next >>

salud ciencia tec 2022; 2 (1)

Sobrevida de pacientes con diagnóstico de Linfoma tipo Burkitt en portadores del Virus de Inmunodeficiencia Humana

Maldonado PBE, Coyago IJA, Maldonado PJE, Barros NDL

Language: Spanish
References: 30
Page:
PDF size: 422.61 Kb.


ABSTRACT

Introduction: Burkitt’s lymphoma (BL) is one of the most common neoplasms in patients with human immunodeficiency virus (HIV), due to the immune compromise they present. Patients with BZL who are HIV carriers have a survival rate of approximately 69 % two years after diagnosis.
Aim: to describe the survival of patients diagnosed with Burkitt’s lymphoma in carriers of the Human Immunodeficiency Virus.
Methodology: a narrative bibliographic review was carried out; for the bibliographic search information collected from the Pubmed database was used.
Results: patients with HIV have a higher incidence of Burkitt type lymphoma due to their immunosuppression, so it is important that they adhere correctly to antiretroviral treatment and chemotherapy, since the survival of the mimics is between 45 % and 50 % 2 years after diagnosis.
Conclusions: HIV carrier patients are approximately 100 times more likely to develop Burkitt’s lymphoma due to their deficient immune system. Currently, antiretroviral treatment has played a very important role in giving HIV carriers a fairly good quality of life.


REFERENCES

  1. Jacoby E, Kahl AR, Jatta A, Kolm-Valdivia N, Brubaker J, Charlton ME, et al. Cancer in the HIV/AIDS Population in Iowa, 1991–2015. J Registry Manag 2019;46:4-14.

  2. Abrahão R, Li QW, Malogolowkin MH, Alvarez EM, Ribeiro RC, Wun T, et al. Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study. Br J Haematol 2020;190:371-84. https://doi.org/10.1111/bjh.16539.

  3. Erlandson KM, Karris MY. HIV and Aging: Reconsidering the Approach to Management of Co-Morbidities. Infect Dis Clin North Am 2019;33:769-86. https://doi.org/10.1016/j.idc.2019.04.005.

  4. Organización Mundial de la Salud. Infección por el VIH. 2022. https://www.who.int/es/news-room/fact-sheets/detail/hiv-aids.

  5. Hernández I, Barzallo J, Beltrán S, Castillo A, Cevallos N, Hernández P, et al. Increased incidences of noninfectious comorbidities among aging populations living with human immunodeficiency virus in Ecuador: a multicenter retrospective analysis. HIV AIDS (Auckl) 2019;11:55-9. https://doi.org/10.2147/HIV.S193412.

  6. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim S-H, Vaca R, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021;137:374-86. https://doi.org/10.1182/blood.2020006926.

  7. Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, et al. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma. J Immunother Cancer 2021;9:e002097. https://doi.org/10.1136/jitc-2020-002097.

  8. Zayac AS, Olszewski AJ. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leuk Lymphoma 2020;61:1784-96. https://doi.org/10.1080/10428194.2020.1747068.

  9. Navarro J-T, Moltó J, Tapia G, Ribera J-M. Hodgkin Lymphoma in People Living with HIV. Cancers (Basel) 2021;13:4366. https://doi.org/10.3390/cancers13174366.

  10. Torres C, Santana J, Bravo R, Córdova L, Rodríguez X, Mardones M, et al. Linfoma de Burkitt asociado a Virus de la Inmunodeficiencia Humana. Reporte de un caso clínico. Revista clínica de periodoncia, implantología y rehabilitación oral 2019;12:148-50. https://doi.org/10.4067/S0719-01072019000300148.

  11. Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkitt lymphoma. The Lancet Haematology2020;7:e594-600. https://doi.org/10.1016/S2352-3026(20)30126-5.

  12. Noy A. HIV-associated lymphoma including Burkitt in the general population. Cancer J 2020;26:260-8. https://doi.org/10.1097/PPO.0000000000000448.

  13. Hübel K. The Changing Landscape of Lymphoma Associated with HIV Infection. Curr Oncol Rep 2020;22:111. https://doi.org/10.1007/s11912-020-00973-0.

  14. Abdelmahmuod EA, Abdulgayoom M, Elhadi M, Magboul H, Sharaf Eldean MZ, Alatasi S. Isolated Oculomotor Cranial Nerve Palsy as Unusual Presentation of Primary High-Grade Burkitt’s Cell Lymphoma in HIV Patient: Case Report and Literature Review. Case Rep Oncol 2021;14:1555-60. https://doi.org/10.1159/000514983.

  15. Komatsu N, Kawase-Koga Y, Mori Y, Kamikubo Y, Kurokawa M, Takato T. HIV-associated Burkitt lymphoma in a Japanese patient with early submandibular swelling. BMC Res Notes 2013;6:557. https://doi.org/10.1186/1756-0500-6-557.

  16. Matsunaga A, Hishima T, Tanaka N, Yamasaki M, Yoshida L, Mochizuki M, et al. DNA methylation profiling can classify HIV-associated lymphomas. AIDS 2014;28:503. https://doi.org/10.1097/QAD.0000000000000120.

  17. Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hübel K. HIV-Associated Malignant Lymphoma. Oncol Res Treat 2017;40:82-7. https://doi.org/10.1159/000456036.

  18. Pinisetti S, Nalabolu GRK, UVR C, Tadi DP. HIV Associated Intra–oral Burkitt’s Lymphoma: A Case Report. J Clin Diagn Res 2013;7:3088-9. https://doi.org/10.7860/JCDR/2013/6715.3862.

  19. Alvarez W, Lai LH, Grant SJ, Sabath DE, Dillon J. Burkitt lymphoma of the maxilla in a HIV positive male – Presentation and review of diagnostic laboratory tests. Oral Maxillofac Surg Cases 2019;5:100113. https://doi.org/10.1016/j.omsc.2019.100113.

  20. Silva WF da, Garibaldi PMM, Rosa LI da, Bellesso M, Clé DV, Delamain MT, et al. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates – A multicenter cohort study. Leukemia Research 2020;89:106287. https://doi.org/10.1016/j.leukres.2019.106287.

  21. Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Medicine 2018; 19:523-531. https://doi.org/10.1111/hiv.12624.

  22. Roy SF, Ghazawi FM, Le M, Lagacé F, Roy CF, Rahme E, et al. Epidemiology of adult and pediatric Burkitt lymphoma in Canada: sequelae of the HIV epidemic. Curr Oncol 2020;27:83-9. https://doi.org/10.3747/co.27.5775.

  23. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, et al. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv 2021;5:2852-62. https://doi.org/10.1182/bloodadvances.2021004458.

  24. Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood 2018;132:254-63. https://doi.org/10.1182/blood-2018-04-844472.

  25. Wang C, Liu J, Liu Y. Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies. Front Oncol 2022;11:798008. https://doi.org/10.3389/fonc.2021.798008.

  26. Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, et al. A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial. British Journal of Haematology 2021;192:119-28. https://doi.org/10.1111/bjh.17188.

  27. Castelli R, Schiavon R, Preti C, Ferraris L. HIV-Related Lymphoproliferative Diseases in the Era ofCombination Antiretroviral Therapy. Cardiovasc Hematol Disord Drug Targets 2020;20:175-80. https://doi.org/10.2174/1871529X20666200415121009.

  28. Zhang R, Sun J. A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy. Transl Cancer Res 2022;11:1806-12. https://doi.org/10.21037/tcr-22-1375.

  29. Rahmat LT, Brandt PH, Ali SS. The first reported case of vincristine‐induced unilateral vocal cord palsy in an adult patient with HIV‐associated Burkitt‐like lymphoma being treated with dose‐escalated R‐EPOCH. Clin Case Rep 2018;7:272-4. https://doi.org/10.1002/ccr3.1964.

  30. Clark E, Royse KE, Dong Y, Chang E, Raychaudhury S, Kramer J, et al. Stable Incidence and Poor Survival for HIV-Related Burkitt Lymphoma Among the U.S. Veteran Population During the Anti-Retroviral Era. J Acquir Immune Defic Syndr 2020;84:18-25. https://doi.org/10.1097/QAI.0000000000002303.




2020     |     www.medigraphic.com